TEDA BIOMEDICAL (08189) has announced that the group expects to record a loss attributable to shareholders of approximately RMB 85 million for the fiscal year ending December 31, 2025. This compares to a loss attributable to shareholders of RMB 27.8022 million for the year ended December 31, 2024.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.